Myelodysplastic syndromes are a diverse and common group of chronic hematologic cancers. The identification of new genetic lesions could facilitate new diagnostic and therapeutic strategies. We used ...

Recurrent mutations in core splicing factors have been reported in several clonal disorders, including cancers. Mutations in SF3B1, a component of the U2 splicing complex, are the most common. SF3B1 ...

A new proof-of-concept method reliably engineered a hotspot mutation of SF3B1, a gene-splicing gene, into diverse cancer cell lines, outperforming other contemporary editing approaches. Oncogenesis ...

Genetic mutations are the spark and fuel for cancer. Hundreds of DNA mutations have been linked to human cancers, and they’re easier than ever to find and catalog, thanks to new genomic technologies.

A new, multicenter study led by Fred Hutchinson Cancer Research Center and Memorial Sloan Kettering Cancer Center determined how a single mutation in splicing factor 3b subunit 1 (SF3B1), the most ...

In a special report published today in the journal Blood, an international working group of experts in myelodysplastic syndromes (MDS) proposes—for the first time—the recognition of a distinct subtype ...

The genetic defects that cause cancer offer potential therapeutic targets. Now, researchers are targeting some of these genes—those essential to cell survival—to specifically kill cancer cells. SF3B1 ...

Melanomas that develop in the eye often are fatal. Now, scientists report they have identified a mutated gene in melanoma tumors of the eye that appears to predict a good outcome. Melanomas that ...